Day: June 2, 2021

NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) — Cowen Inc. (NASDAQ:COWN) (“Cowen” or the “Company”) today announced that Gary Taylor has joined the Company’s equity research department to cover health care facilities and managed care stocks. He will be focused on both legacy and emerging health care payors and providers. Gary will report to Robert Fagin, Cowen’s Director of Research. “Over the nearly 20 years that I have known Gary, his research has earned him a reputation for being insightful, thematic, and actionable. Combined with the strong management relationships he has formed, he is an extraordinary analyst, and embodies the thought leadership, creativity and intensity that represents the Cowen research brand. I am thrilled to have him as part of the Cowen team,” said Mr. Fagin. Cowen’s research department has 54 senior analysts...

WHITTIER, Calif. and WALL, N.J., June 02, 2021 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), an innovative provider of identity and access management (IAM) solutions featuring biometrics, today announced that Rio Hondo College in Whittier, CA, with more than 19,000 students has selected BIO-key’s PortalGuard Identity-as-a-Service (IDaaS) platform to improve their security posture and user experience for access to more than twenty enterprise applications such as Ellucian Banner, Brightspace, Canvas LMS and Microsoft Office 365. The IT team at Rio Hondo College is focused on improving the user experience and streamlining access to critical applications through PortalGuard’s Single Sign-On (SSO) capabilities. Providing an array of valuable applications enhances the student experience, but remembering multiple...

COMPANY ANNOUNCEMENT NO. 28/2021 – 2 JUNE 2021 At Royal Unibrew A/S’ Annual General Meeting on 28 April 2021 a resolution was adopted, following a proposal by the Board of Directors, to reduce the Company’s share capital by a nominal amount of DKK 1,100,000 from nominally DKK 98,700,000 to DKK 97,600,000 by cancelling 550,000 treasury shares of a nominal value of DKK 2 each. The capital reduction has been implemented and registered with the Danish Business Authority today. After the reduction the Company’s share capital is nominally DKK 97,600,000 divided into shares of DKK 2. The revised Articles of Association can be found on the Company’s website www.royalunibrew.com under Investor, Corporate Governance. After the cancellation of treasury shares, the Company’s holding of treasury shares represents 474,120 number of shares (of nominally...

Figure 1Feni Project, map showing prospects on magnetics – the drilling program will focus on the Kabang prospect where geophysical targets will be tested (see Fig. 2). Other prospects will be the subject of ongoing exploration.Figure 2Feni DDIP Survey 3D Phase Inversion Model 200m depth slice, with summary interpretation of conductive zone (resistivity < 10 Ωm) superimposed. Proposed drill holes are testing the porphyry copper / gold target to 500m depth (see Figure 3), in addition to testing the shallower epithermal gold zones.Figure 3Perspective view looking to the south-west of the 3D inversion model showing the modelled sub-vertical pipe-like zone porphyry Cu/Au drilling target at Kabang (see Fig 1). As can be seen, the zone is largely untested and extends deeper than the current...

FRAMINGHAM, Mass., June 02, 2021 (GLOBE NEWSWIRE) — Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), developer of novel self-assembling wound care and biosurgical devices, today announced that it will be presented virtually at the upcoming LD Micro Invitational XI event. Chief Executive Officer, Terrence W. Norchi, MD, and Chief Financial Officer, Mike Abrams, are scheduled to present via webcast, which will be available on-demand as of 4:15 PM ET, Thursday, Jun. 10, 2021.  You may access & register for the live webcast at https://ldmicrojune2021.mysequire.com/. After the event, the presentation will be available at https://ir.archtherapeutics.com/presentations. About Arch Therapeutics, Inc.Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control...